Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04927884 · ClinicalTrials.gov registry record · Phase 1
A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies
A Phase 1 study, sponsored by ImmunityBio.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT04927884 is a Phase 1 study that was terminated before completion, run by ImmunityBio. The registered enrollment target is 3 participants.
The verdict
NCT04927884, a Phase 1 study, was terminated before completion, sponsored by ImmunityBio.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is a phase 1b/2 open-label study to evaluate the safety and efficacy of sacituzumab govitecan-hziy in combination with chemoimmunotherapy (cyclophosphamide, N-803, and PD-L1 t-haNK) in subjects with Triple Negative Breast Cancer (TNBC) after at least 2 prior treatments for metastatic disease.
Interventions
- DRUG Cyclophosphamide
- BIOLOGICAL PD-L1 t-haNK
- BIOLOGICAL N-803
- DRUG Sacituzumab Govitecan-Hziy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2021-09-08 |
| Est. Completion | 2022-12-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04927884
The ClinicalTrials.gov registry entry for NCT04927884 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunityBio, which has 46 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT04927884 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04927884 about?
NCT04927884 is a clinical study titled "A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies". This is a phase 1b/2 open-label study to evaluate the safety and efficacy of sacituzumab govitecan-hziy in combination with chemoimmunotherapy (cyclophosphamide, N-803, and PD-L1 t-haNK) in subjects with Triple Negative Breast Cancer (TNBC) after at least 2 prior treatments for metastatic disease.
What is the current status of trial NCT04927884?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2021-09-08. Estimated completion is 2022-12-12.
What interventions are being tested in trial NCT04927884?
The interventions under investigation include: Cyclophosphamide (DRUG), PD-L1 t-haNK (BIOLOGICAL), N-803 (BIOLOGICAL), Sacituzumab Govitecan-Hziy (DRUG).
Who is sponsoring clinical trial NCT04927884?
This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.